Pomegra
Eli Lilly Stock Rises 3% After China Approves Weight-Loss Pill
Why is Eli Lilly stock up today?
Eli Lilly (LLY) stock rose about 3% on Thursday to above $1,470 in early trading after China approved its weight-loss pill orforglipron, the first oral GLP-1 drug cleared there, ahead of Novo Nordisk.
Key numbers
| LLY premarket move | +2.8%after China approval |
|---|---|
| Early move range | +1.2% to 3%+reports differ by time of day |
| Q3 2026 revenue | $24.4B+39% YoY |
| 2026 revenue guidance | $91–92Bup from $85–87B |
| Foundayo Q3 sales | $184Mnew 2026 launch |
| Weight loss in trials | ~11%over 72 weeks (per [6]) |
What happened
Eli Lilly (LLY) stock rose about 3% on Thursday to above $1,470 in early trading after China approved its weight-loss pill orforglipron, the first oral GLP-1 drug cleared there, ahead of Novo Nordisk. It is the first weight-loss pill China has cleared; until now, only injections were approved there. Novo Nordisk's pill version of Wegovy is still under review, and Lilly applied first. In trials, Lilly's pill cut body weight about 11% over 72 weeks, versus about 14% over 64 weeks for Novo's pill.
Why it matters
Eli Lilly now has a head start selling a weight-loss pill in China, the world's second-largest drug market, where more than 500 million adults are overweight or obese. A daily tablet may be easier for some people than an injection, which could widen the number of patients. Patients in China pay for these drugs themselves, because public health insurance does not cover them. Novo Nordisk must wait for its own approval.
Who this affects
- MarketmixedLow impact
- Drug investors: Lilly gains, Novo faces a delay in China.
- CompanybullishMedium impact
- Good for Lilly shareholders: first pill on sale in China.
- CompetitorsbearishMedium impact
- Bad for Novo Nordisk: loses first-mover edge in China's pill market.
- IndustrymixedMedium impact
- More obesity options in China; injection makers now face a pill.
Eli Lilly vs Novo Nordisk, Pfizer, Innovent
How we got here
Novo Nordisk's oral Wegovy application accepted for review in China.
Lilly reports Q3 revenue up 39% to $24.4B and raises 2026 guidance.
China approves orforglipron; Lilly shares rise about 3% in early trading.
What to watch
- China's decision on Novo Nordisk's oral Wegovy, still under review.No date set
- China's review of orforglipron for type 2 diabetes, now pending.No date set
- Lilly's next quarterly report, with Foundayo sales after Q3's $184M.Q4 2026
Educational content only. Not investment advice.
More briefsAll briefs →
Strategy Stock Falls 6% After MSCI Index Removal
Strategy (MSTR), formerly MicroStrategy, faces an estimated $2.8B of forced selling by index funds.
Legence Stock Jumps 13.7% Ahead of Q3 Earnings
Legence (LGN) rose to $36.45 as CoreWeave's strong report lifted data-center builders before earnings.
Fed Rate Peak Rises to 4.5% as Goldman Adds Hike on Inflation
Goldman Sachs (GS) now sees two more quarter-point hikes, as October prices rose 0.4% and Goolsbee warned.